Hear what physicians have to say about the challenges of treating the SFA and how drug-eluting stents may help improve patient outcomes.
Physicians talk about the importance of drug-eluting stents in complex lesions and how the Eluvia Drug-Eluting Stent is fine-tuned to produce a sustainable release of paclitaxel over time.
See how over a decade of research helped Eluvia engineers develop the first drug-eluting stent for the SFA designed to sustain drug release when restenosis is most likely.
See what physicians are saying about the unprecedented clinical outcomes for the Eluvia Drug-Eluting Stent, including two-year primary patency and TLR rates.
Physicians discuss the tuned paclitaxel elution profile of the Eluvia Drug-Eluting Stent and how the stent has demonstrated unprecedented efficacy data in patients with peripheral artery disease (PAD).
An innovative treatment option that sustains drug release beyond one year and has shown unprecedented clinical data outcomes in the SFA.
Delivers paclitaxel when restenosis is most likely.
Unprecedented clinical data outcomes in the SFA.
Built on the proven InnovaTM Stent platform.